HR Execs on the Move

Virpax Pharmaceuticals

www.virpaxpharma.com

 
Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Christopher Chipman
 Chief Financial Officer Profile
Vinay Shah
 Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer Profile

Similar Companies

International Stem Cell Corporation

International Stem Cell Corporation is a Oceanside, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Tetragenex Pharmaceuticals

Tetragenex Pharmaceuticals is a Syosset, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IntriCon

More than an OEM company, IntriCon is invested in creating a hearing healthcare system to offer individuals hearing help at a cost they can afford.

Cychem

Cychem, Inc. is a Westlake Village, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.